Dr Sylwia Ammoun
Profiles

Dr Sylwia Ammoun

Senior Research Fellow

Peninsula Medical School (Faculty of Health)

Biography

Biography

Education and qualifications

  • 2005 PhD dissertation, Uppsala University, Sweden, Orexin Receptors in Recombinant CHO Cells. Signaling to Short- and Long Term Cells responses
  • 2004 Transfer, Uppsala University, Sweden
  • 1997 Degree of Master of Science, Uppsala University, Sweden Immunomodulatory-and-cytokine gene-cancer therapy
  • 1996 BScs, Uppsala University, Sweden

Professional membership

Member of South of England Brain Tumour Alliance (SEBTA)

Teaching

Teaching

Teaching interests

Teaching experience

I enjoy sharing my knowledge and always appreciate teaching in which I have 18 years of experience.

Uppsala University, Sweden  

From 1998 to 2005 I taught medical-, pharmacology- and nurse-students in the following subjects: hemodynamics (blood-vascular circulation-system), the safety of medical equipment (current), optical refraction of the eye, heart anatomy (dissection), oscilloscope and pacemaker and muscle structure and function. During this time I also supervised undergraduate and BSc biomedical students and lab assistants.

Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK

From 2006 until present I have supervised PhD, BSc, and undergraduate students in different projects. Between 2006 and 2007 I taught medical students in 'Neurodegenerativedisorders' and 'Disease prevention and management-vaccines ‘and 2019 biomedical students in 'Tumours of the nervous system'.

Teaching education

  • 2014 Internal and External Doctoral Examiners training
  • 2011 Learning and Teaching for general Teaching Associates (GTA) training including: Theories of Learning and Teaching, Planning Sessions and Delivering Presentations, Learning in Groups, Evaluating Teaching and Giving Feedback, Assessment, Dealing with difficult Situations and Assessment Criteria and Marketing.
  • 2008 Problem-based learning (PBL) facilitator training.

Research

Research

Research interests

Research interests and experience

During my career I have been working on different projects including: 1) The development of immunomodulatory cancer vaccines to treat Acute Myeloid Leukaemia (AML) (Clinical Immunology),2)Investigation of the role of endogenous retroviruses in Multiple Sclerosis(MS)(Clinical Virology) and 3) Revealing the signalling of orexinergic receptors towards cell fate determination (Neuroscience).

Since January 2006 I have been working at Professor Oliver Hanemann’s laboratory (Plymouth University Peninsula Schools of Medicine and Dentistry, The Institute of Translational and StratifiedMedicine). My work has centred on dissecting the signalling pathways involved in the development of Merlin-deficient tumours in order to find specific and effective therapeutic targets. I have successfully achieved external funding from six different charities where I was lead or single applicant. Additionally, I have published ten first-authored papers, one paper as Director of studies and one book chapter and one invited article in Nature Reviews Neurology. I have also contributed to six other papers published by my colleagues. 

Ph.D. studentssupervision: three PhD students- first supervisor (DoS, onecompleted2018), 1- co-supervisor (DoS, completed 2018), 1- co-supervisor. 

Our research team have received an award from Neurofibromatosis (NF) Advocature in recognition of our research and continued commitment to NF2. Additionally, my work within theNF2 field contributed to phase 0 clinical trials at our unit in collaboration with Manchester Hospital. My main goal is to find a good drug treatment for schwannomas and other Merlin-deficient tumours.

Other research

Previous projects

2011-2013

1.   p53/mouse double minute 2homolog complex deregulation in Merlin-deficient tumours

This project involved the investigation of the role of p53 deregulation in schwannoma development and targeting pathways involved in p53 degradation. In this project, I was first author.

2.  Gas6/Axl-family receptors in schwannoma pathological proliferation, adhesion and survival

In this project, we have investigated the role of Axl receptor inschwannoma pathological proliferation, cell-matrix adhesion, and survival. In this project, I was the first and corresponding author.

2010-2012

1.  The role of insulin-like growth factors (IGF1/2) signalling inMerlin-deficient human schwannomas

2.  Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannomaproliferation, adhesion and survival

In these studies, we have demonstrated that IGF1/2 and IGFBP-1 arereleased from schwannoma cells and IGF-I receptor overexpressed leading toincreased schwannoma proliferation and cell-matrix adhesion. In these projects I was first author.

2010-2011

Nilotinib alone or incombination with selumetinib is a drug candidate for neurofibromatosis type 2

In this project we have tested the therapeutic effectiveness of a PDGFRinhibitor Nilotinib and a MEK1/2 inhibitor selumetinib (AZD6244), in humanschwannoma in vitro model. In these projects I was firstauthor.

2009-2010

ErbB/HER receptoractivation and preclinical efficacy of lapatinib in vestibular schwannoma

This project was in collaboration with Dr Karajannis (USA) to test EGFR/HER inhibitor Lapatinib in human schwannoma in vitro model. In these projects I shared first authorship.

2008-2009

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitorAZD6244

In this study, we have tested the therapeutic effectiveness of a MEK1/2inhibitor AZD6244, in human schwannoma in vitro model. In these projects I was first author.

2007-2008

Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma

Here we demonstrated that PDGFRβ is strongly overexpressed in schwannoma cells leading to increased schwannoma proliferation. We have also successfully tested a PDGFR/Raf inhibitor Sorafenib. In these projects, I was the first author.

1999-2005

PhD project                                                                                          

Orexin Receptors in Recombinant CHO Cells. Signaling to Short- and Long Term Cells responses

The aim of this study was to investigate the mechanisms of orexin receptor coupling to the cascades regulating cell fate and also the assessment of the molecular determinants involved in orexin peptide-orexin receptor interaction.

1997-1998

Research project

Endogenous retroviruses in neurodegenerative diseases

This project focused on the investigation of the expression of the endogenous retrovirus (ERV9)-related proteins in peripheral blood cells and presence in sera from multiple sclerosis (MS) patients.

1996-1997

MSc research project

Immunomodulatory-and-cytokine gene-cancer therapy

The aim of this was to design cancer vaccines to treat leukemia and lymphoma. The vaccines would be implemented in both immunotherapy and gene therapy. For immunotherapy, human blood monocytes were separated and differentiated into dendritic cells for antigen presentation and activation of cellular immunity. For cytokine gene therapy, genes for various cytokines were transferred into acute myeloid leukemia (AML) cells via retrovirus- and adenovirus-based vectors.

2011-2019

Clinical Research

I was involved in phase 0 clinical trials testing Sorafenib in Neurofibromatosis type 2 (NF2) patients. I perform tests on tumour tissue and blood samples from patients to look for the effect of these drugs on signalling pathways known to be involved in the development of Merlin-deficient tumours.

Research degrees awarded to supervised students

Supervisor of Ph.D. students: 3- first supervisor (DoS), 1- co-supervisor (DoS), 1- co-supervisor.

Grants & contracts

Research grants

2018  AnimalFree UK charity 01/08/2018-30/09/2018; ‘Investigating the role of TYRO3, AXL and MERTK(TAM) receptors in Merlin deficient brain tumours; schwannomas andmeningioma’:£1,940.00.

2018 GreatOrmond Street Hospital Children'sCharity Grants: ‘Investigation and targeting cellular prion protein PrPC in neurofibromatosis type II related tumoursschwannomas, meningiomas and spinal ependymomas. Sylwia Ammoun: lead applicant and DoS; Oliver Hanemannco-applicant. £112,000, two years.

2016 ActionMedicalResearch for children: ‘The role of Endogenous Retroviral proteins in the development of Merlin-deficient tumours and as potential immunotherapy and/or drug targets’. Sylwia Ammoun: lead applicant and DoS, RobertBelshaw:co-applicant. September 2016-September 2018. Consumables£65,061.                                  

2015 InternalPhDstipend: ‘Endogenous Retroviral proteins as potential drug targets for Merlyn-deficient tumours and their role in tumour development.Sylwia Ammoun: lead applicant andDoS, Robert Belshaw: co-applicant. November 2016-November 2019. Student’s stipend, £61,000.

2014   Action on Hearing Loss Flexi grant, ‘Endogenous Retroviral proteins as potential immunotherapy and/or drug targets for Merlin-deficient tumours treatment and their role in vestibular neuroma development’. Sylwia Ammoun: lead applicant and DoS, Robert Belshaw: co-applicant. November 2014-April2014.Consumables £4697.

2014   TheLaura Crane Youth Cancer Trust grant, ‘The role of prion proteinsinMerlin-deficient tumours’. Sylwia Ammon: principal applicant and DoS.October2014-October 2016. Consumables £24,000.

2013 InternalPhDstipend. ‘The role of cellular prion proteins in schwannoma and otherMerlin-deficient tumours’. Sylwia Ammoun: Principal applicant and DoS.October2013-October 2016. Student’s stipend £61,000.

2009 Northcott Devon Medical Foundation project grant, single applicant. The role of Insulinlike growth factors in schwannoma development.£5,000.

Publications

Publications

Key publications

Key publications are highlighted

Journals
Articles
Sofela AA, Hilton DA, Ammoun S, Baiz D, Adams CL, Ercolano E, Jenkinson MD, Kurian KM, Teo M & Whitfield PC (2021) 'Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas' International Journal of Molecular Sciences 22, (2) 560-560 , DOI Open access
Hanemann CO, Ammoun S, Evans G, Hilton DA, Streeter A & Hayward C (2019) 'Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type 2' Journal of Neurology, Neurosurgery and Psychiatry , DOI Open access
Stepanova DS, Semenova G, Kuo Y-M, Andrews AJ, Ammoun S, Hanemann CO & Chernoff J (2017) 'An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis' Cancer Research Author Site , DOI Open access
Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S & Hanemann CO (2017) 'Cellular prion protein (PrPC) in the development of Merlin-deficient tumours' Oncogene , DOI Open access
Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I & Barczyk M (2015) 'The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors' Oncogene 35, (26) 3443-3453 , DOI Open access
Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M & Hanemann CO (2015) 'The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours' Mol Oncol 9, (1) 236-248 Author Site , DOI
Ammoun S, Provenzano L, Zhou L, Schmid MC & Hanemann CO (2014) 'IDENTIFICATION AND TARGETING PATHWAYS INVOLVED IN THE DEVELOPMENT OF MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 5805-5805 Author Site
Provenzano L, Ammoun S & Hanemann CO (2014) 'THE ROLE OF CELLULAR PRION PROTEIN IN SCHWANNOMA AND OTHER MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 6123-6123 Author Site
Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW & Dombi E (2014) 'CTF Meeting 2012: Translation of the Basic Understanding of the Biology and Genetics of NF1, NF2, and Schwannomatosis Toward the Development of Effective Therapies' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 164, (3) 563-578 Author Site , DOI
Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S & Hanemann CO (2014) 'Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival' Oncogene 33, (3) 336-346 Author Site , DOI Open access
Shivane A, Parkinson DB, Ammoun S & Hanemann CO (2013) 'Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas' HISTOPATHOLOGY 62, (4) 651-656 Author Site , DOI
Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C & Hanemann CO (2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 Author Site , DOI Open access
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM & Hanemann CO (2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO. Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20' Glia
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM & Hanemann CO (2012) 'Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival' Oncogene 31, (13) 1710-1722 Author Site , DOI
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA & Hanemann CO (2011) 'Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways' Neoplasia 13, (12) 1101-1112 Author Site , DOI
Ammoun S, Schmid MC, Triner J, Manley P & Hanemann CO (2011) 'Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2' Neuro Oncol 13, (7) 759-766 Author Site , DOI
Ammoun S & Hanemann CO (2011) 'Emerging therapeutic targets in schwannomas and other merlin-deficient tumors' Nat Rev Neurol 7, (7) 392-399 Author Site , DOI
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA (2010) 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol 12, (8) 834-843 Author Site , DOI
Ammoun S, Ristic N, Matthies C, Hilton DA & Hanemann CO (2010) 'Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244' Neurobiol Dis 37, (1) 141-146 Author Site , DOI
Flaiz C, Chernoff J, Ammoun S, Peterson JR & Hanemann CO (2009) 'PAK kinase regulates Rac GTPase and is a potential target in human schwannomas' Exp Neurol 218, (1) 137-144 Author Site , DOI
Ammoun S (2009) 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Flaiz, Christine; Ammoun, Sylwia; Biebl, Anja; Hanemann, C. Oliver. Brain Pathology, Volume 19, Number 1, January 2009, pp. 27-38(12)'
Flaiz C, Ammoun S, Biebl A & Hanemann CO (2009) 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma' Brain Pathol 19, (1) 27-38 Author Site , DOI
Ammoun S, Flaiz C, Ristic N, Schuldt J & Hanemann CO (2008) 'Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma' Cancer Res 68, (13) 5236-5245 Author Site , DOI
Ammoun S & Hanemann O (2007) 'Strong and long-lasting activation of ERK in human schwannoma cells' Neuropathology and Applied Neurobiology 33, (2) 258-259
Ammoun S (2006) 'OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling. Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, Akerman KE, Kukkonen JP. Mol Endocrinol. 2006 Jan;20(1):80-99. Epub 2005 Sep 1'
Ammoun S (2006) 'G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase. Ammoun S, Lindholm D, Wootz H, Akerman KE, Kukkonen JP. J Biol Chem. 2006 Jan 13;281(2):834-42. Epub 2005 Nov 10'
Ammoun S, Lindholm D, Wootz H, Åkerman KEO & Kukkonen JP (2006) 'G-protein-coupled OX1 Orexin/hcrtr-1 Hypocretin Receptors Induce Caspase-dependent and -independent Cell Death through p38 Mitogen-/Stress-activated Protein Kinase' Journal of Biological Chemistry 281, (2) 834-842 , DOI
Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, Åkerman KEO & Kukkonen JP (2006) 'OX1Orexin Receptors Activate Extracellular Signal-Regulated Kinase in Chinese Hamster Ovary Cells via Multiple Mechanisms: The Role of Ca2+Influx in OX1Receptor Signaling' Molecular Endocrinology 20, (1) 80-99 , DOI
Ammoun S (2005) 'OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. Holmqvist T, Johansson L, Ostman M, Ammoun S, Akerman KE, Kukkonen JP. J Biol Chem. 2005 Feb 25;280(8):6570-9'
Holmqvist T, Johansson L, Östman M, Ammoun S, Åkerman KEO & Kukkonen JP (2005) 'OX1 Orexin Receptors Couple to Adenylyl Cyclase Regulation via Multiple Mechanisms' Journal of Biological Chemistry 280, (8) 6570-6579 , DOI
Kukkonen JP, Holmqvist T, Ammoun S & Åkerman KEO (2003) 'Erratum: Functions of the orexinergic/hypocretinergic system (American Journal of Physiology - Cell Physiology (December 2002) 283 (c1567-c1591))' American Journal of Physiology - Cell Physiology 284, (4 53-4)
Ammoun S (2003) 'Distinct recognition of OX1 and OX2 receptors by orexin peptides. Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, Akerman KE, Kukkonen JP. J Pharmacol Exp Ther. 2003 May;305(2):507-14. Epub 2003 Jan 24'
Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, Åkerman KEO & Kukkonen JP (2003) 'Distinct Recognition of OX1 and OX2Receptors by Orexin Peptides' Journal of Pharmacology and Experimental Therapeutics 305, (2) 507-514 , DOI
Ammoun S (2002) 'Functions of the orexinergic/hypocretinergic system. Kukkonen JP, Holmqvist T, Ammoun S, Akerman KE. Am J Physiol Cell Physiol. 2002 Dec;283(6):C1567-91. Review. Erratum in: Am J Physiol Cell Physiol. 2003 Apr;284(4)'
Kukkonen JP, Holmqvist T, Ammoun S & Åkerman KEO (2002) 'Functions of the orexinergic/hypocretinergic system' American Journal of Physiology-Cell Physiology 283, (6) C1567-C1591 , DOI
Nasman J, Kukkonen JP, Ammoun S & Akerman KEO (2001) 'Role of G-protein availability in differential signaling by alpha 2-adrenoceptors 1 1Abbreviations: α2-AR, α2-adrenergic receptor; AC, adenylyl cyclase; GTPγS, guanosine 5′-O-(3-thiotriphosphate); IBMX, 3-isobutyl-1-methyl-xanthine; UK14,304, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine' Biochemical Pharmacology 62, (7) 913-922 , DOI
Ammoun S (2001) 'Role of G-protein availability in differential signaling by alpha 2-adrenoceptors. Nasman J, Kukkonen JP, Ammoun S, Akerman KE. Biochem Pharmacol. 2001 Oct 1;62(7):913-22'
Ammoun S (2000) 'Recombinant expression of a selective blocker of M(1) muscarinic receptors. Näsman J, Jolkkonen M, Ammoun S, Karlsson E, Akerman KE. Biochem Biophys Res Commun. 2000 May 10;271(2):435-9'
Näsman J, Jolkkonen M, Ammoun S, Karlsson E & Åkerman KEO (2000) 'Recombinant Expression of a Selective Blocker of M1 Muscarinic Receptors' Biochemical and Biophysical Research Communications 271, (2) 435-439 , DOI
Olsson P, Ryberg B, Awad R, Ammoun S, Yin H, Hjalmarsson S & Blomberg J (1999) 'Retroviral RNA Related to ERV9/MSRV in a Human Serum: A New Sequence Variant' AIDS Research and Human Retroviruses 15, (6) 591-593 , DOI
Ammoun S (1999) 'Retroviral RNA related to ERV9/MSRV in a human serum: a new sequence variant. Olsson P, Ryberg B, Awad R, Ammoun S, Yin H, Hjalmarsson S, Blomberg J. AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):591-3'
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro-oncology Publisher Site , DOI Open access
Chapters
Publisher BS (2012) 'Receptor Tyrosine Kinases in Human Schwannoma' Angiogenesis & Therapeutic Targets In Cancer BENTHAM SCIENCE PUBLISHERS 90-98 , DOI
Conference Papers
Maze E, Reeves S, Hilton D, Provenzano L, Belshaw R & Ammoun S (2016) 'Abstract 4627: The role of human endogenous retroviral proteins in the development of Merlin-deficient tumors and as potential drug targets' Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA American Association for Cancer Research , DOI
Hanemann CO, Zhou L, Ammoun S, Lasonder E, Sharma V, Muller J & Ercolano E (2015) 'Abstract 704: Scaffold protein KSR1 is negatively regulated by merlin and promotes tumor development in merlin deficient tumors' Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA American Association for Cancer Research , DOI
Hanemann CO, Ammoun S, Schmid MC & Zhou L (2014) 'Abstract 2609: The role of focal adhesion kinase (FAK), PI3K/AKT and p53/mouse double minute 2 homologue (MDM2) complex in the pathobiology of Merlin-deficient tumors' Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA American Association for Cancer Research , DOI
Hilton D, Shivane A, Kirk L, Ammoun S & Hanemann CO (2014) 'Growth factor signaling pathway activation in meningiomas' 101-101
Hilton DA, Shivane A, Turner L, Ammoun S & Hanemann O (2013) 'Activation of multiple signalling pathways in meningiomas is unrelated to NF2 gene status' 35-35
Shivane A, Ammoun S, Parkinson DB & Hanemann CO (2012) 'EXPRESSION OF C-JUN & SOX-2 IN HUMAN SCHWANNOMAS AND TRAUMATIC NEUROMAS' 9-10
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk M & Hanemann CO (2012) 'MERLIN DEFICIENT HUMAN TUMOURS SHOW LOSS OF CONTACT INHIBITION, ACTIVATION OF WNT/beta-CATENIN SIGNALING LINKED TO THE PDGFR/SRC AND RAC/PAK PATHWAYS' 5-6
Ammoun S, Zhou L, Barczyk M, Hilton D, Hafizi S & Hanemann CO (2011) 'GAS6/AXL-FAMILY RECEPTORS IN SCHWANNOMA PATHOLOGICAL PROLIFERATION, ADHESION AND SURVIVAL' 1-1
Schmid MC, Zhou L, Ammoun S & Hanemann CO (2010) 'Targeting focal adhesion kinase (FAK) in primary human schwannoma' 42-42 , DOI
Hanemann CO, Ammoun S, Schmid MC, Ristic N, Ercolano E & Zhou L (2010) 'IGF/IGFBP SIGNALING IN MERLIN-DEFICIENT TUMORS' 22-22
Hanemann CO & Ammoun S (2009) 'MERLIN'S TUMOURS: FROM BENCH TO BEDSIDE' , DOI
Mackay L, Higgins S, Abderrahim A, Mistry P, Ammoun S, Whitaker G, Akinwunmi J, Hanneman CO & Pilkington GJ (2008) 'IGF-BP1/2 expression in histological sections, biopsy-derived cell cultures and cyst fluids from nervous system neoplasms' 21-21
Ammoun S & Hanemann O (2007) 'Strong and long-lasting activation of ERK in human schwannoma cells' 258-259
Posters
Ammoun S, Dave F, Hilton D, Adams C, Elcorano E, Hafizi S & Hanemann CO Ammoun S, Dave F, Hilton D, Adams C, Elcorano E, Hafizi S & Hanemann CO 'INVESTIGATING THE ROLE OF TAM FAMILY RECEPTORS IN MERLIN DEFICIENT TUMOURS' Author Site